Drug Profile
IBDV R903/78
Alternative Names: HC-001; HC-002; HC-003; IBDV-R903/78 - HepCLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator HepC
- Class Anti-infectives; Antineoplastics; Antivirals; Immunotherapies; Viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Hepatitis B; Hepatitis C
- No development reported Dengue; Ebola virus infections; Liver cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Dengue in Hungary (PO)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Dengue in USA (PO)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Ebola-virus-infections in Hungary (PO)